Life-spanning trajectories and critical events that influence hospitalization and death.
Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease
The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made